CLDX
Celldex Therapeutics, Inc.
$31.27
+4.37%
$2.5B
No data for this timeframe.
Vol
Market Cap$2.5B
Cap SizeMid Cap
Analyst ConsensusStrong Buy (91%)
Inst. Holders50 funds
Inst. Value$1.1B
Inst. Activity10 buys / 4 sells
Reddit Sentiment60° Warm
SEC Reports6
Press Releases7
Exchange Nasdaq·Sector In Vitro & In Vivo Diagnostic Substances·Inc. DE·CIK 0000744218·Prev Close $29.96
Recent Activity
Jun 14, 2026
SEC
Celldex reported Q1 2026 EPS of -$1.18, missing consensus of -$1.07 by 10.8%. The press release focuses on positive long
PRESS-RELEASE — Impact 6/10
Jun 11, 2026
SEC
A mixed institutional cluster in CLDX for Q3 2025 shows two mega-passive buyers (Wells Fargo, Invesco) adding modest pos
INST-CLUSTER — Impact 4/10
May 7, 2026
SEC
Celldex reported Q1 2026 results with a net loss of $78.7M (-$1.18/share), wider than the $53.8M loss (-$0.81/share) in
8-K — Impact 6/10
Inst.
Point72 Asset Management, L.P. — ADD
3,229,939 shares ($102.5M)
Inst.
DIMENSIONAL FUND ADVISORS LP — ADD
1,059,534 shares ($33.6M)
Jun 14, 2026
earnings
Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at the European Academy of Allergy and Clinical Immunology Annual Meeting
<p align="left">HAMPTON, N.J., June 14, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced t
Jun 14, 2026
Press
Celldex presented positive Phase 1 data for CDX-622, a bispecific antibody targeting SCF and TSLP, at EAACI. The drug sh
Impact 7/10
Jun 10, 2026
Press
Celldex announced three presentations at EAACI 2026: two flash talks on barzolvolimab's clinical profile in CSU and cold
Impact 4/10
Price Targets
$57.53
+84.0% upside
Strong Buy
Current $31.27
Low $38.00
Median $54.00
High $90.00
15 analysts
$38.00
$90.00
Analyst Ratings
7Strong Buy
13Buy
2Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Jun 10, 2026 | UBS | MAINTAIN | Buy → Buy |
| May 13, 2026 | Wells Fargo | MAINTAIN | Overweight → Overweight |
| May 8, 2026 | Barclays | MAINTAIN | Overweight → Overweight |
| Apr 20, 2026 | Barclays | UPGRADE | Underweight → Overweight |
| Mar 2, 2026 | Goldman Sachs | MAINTAIN | Neutral → Neutral |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-1.07 | $-1.16 — $-0.92 | -25% YoY | 10 |
| Next Q | $-1.08 | $-1.20 — $-0.94 | -7% YoY | 10 |
| Current FY | $-4.39 | $-4.57 — $-4.03 | -13% YoY | 10 |
| Next FY | $-4.50 ▲ +1.1% | $-5.46 — $-3.78 | -2% YoY | 10 |
Latest Reports
BEARISH
PRESS-RELEASE
6/10
Celldex reported Q1 2026 EPS of -$1.18, missing consensus of -$1.07 by 10.8%. The press release focuses on positive long
Jun 14, 2026
BULLISH
Press
7/10
Celldex presented positive Phase 1 data for CDX-622, a bispecific antibody targeting SCF and TSLP, at EAACI. The drug sh
Jun 14, 2026
NEUTRAL
INST-CLUSTER
4/10
A mixed institutional cluster in CLDX for Q3 2025 shows two mega-passive buyers (Wells Fargo, Invesco) adding modest pos
Jun 11, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| NOMURA ASSET MANAGEMENT CO | — | — |
| WELLINGTON MANAGEMENT GROUP LLP | $271.5M | ADD |
| BlackRock, Inc. | $170.3M | — |
| FMR LLC | $118.9M | — |
| Point72 Asset Management, L.P. | $102.5M | ADD |
Reddit Sentiment
60°
Warm
Bearish
Neutral
Bullish
50 institutional holders with $1.1B total value (36,113,458 shares) as of 2026-Q1. Top holders: NOMURA, WELLINGTON, BlackRock,. Net buying activity: 10 institutions added/increased vs 4 reduced.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | NOMURA ASSET MANAGEMENT CO LTD | — | $0.00 | 0.0% | — |
| 2 | WELLINGTON MANAGEMENT GROUP LLP | 8,560,476 | $271.5M | 23.7% | ADD +39.3% |
| 3 | BlackRock, Inc. | 5,369,885 | $170.3M | 14.9% | — |
| 4 | FMR LLC | 3,749,048 | $118.9M | 10.4% | — |
| 5 | Point72 Asset Management, L.P. | 3,229,939 | $102.5M | 8.9% | ADD +83.7% |
| 6 | VANGUARD CAPITAL MANAGEMENT LLC | 2,960,895 | $93.9M | 8.2% | — |
| 7 | STATE STREET CORP | 2,804,168 | $88.9M | 7.8% | — |
| 8 | DIMENSIONAL FUND ADVISORS LP | 1,059,534 | $33.6M | 2.9% | ADD +62.6% |
| 9 | GOLDMAN SACHS GROUP INC | 988,416 | $31.4M | 2.7% | — |
| 10 | Pictet Asset Management Holding SA | 923,696 | $29.3M | 2.6% | — |
| 11 | BANK OF AMERICA CORP /DE/ | 708,647 | $22.5M | 2.0% | ADD +70.8% |
| 12 | BAKER BROS. ADVISORS LP | 665,370 | $21.1M | 1.8% | — |
| 13 | VANGUARD PORTFOLIO MANAGEMENT LLC | 629,252 | $20.0M | 1.7% | — |
| 14 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 545,486 | $17.3M | 1.5% | — |
| 15 | Woodline Partners LP | 500,127 | $15.9M | 1.4% | DOUBLED +151.0% |
| 16 | VANGUARD FIDUCIARY TRUST CO | 429,597 | $13.6M | 1.2% | — |
| 17 | MORGAN STANLEY | 217,549 | $6.9M | 0.6% | TRIM -52.8% |
| 18 | CITIGROUP INC | 217,335 | $6.9M | 0.6% | — |
| 19 | Nuveen, LLC | 201,949 | $6.4M | 0.6% | — |
| 20 | CITADEL ADVISORS LLC | 200,612 | $6.4M | 0.6% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| Point72 Asset Management, L.P. | ADD | 1,758,357 | 3,229,939 | +83.7% | $102.5M | 2026-Q1 |
| DIMENSIONAL FUND ADVISORS LP | ADD | 651,716 | 1,059,534 | +62.6% | $33.6M | 2026-Q1 |
| BANK OF AMERICA CORP /DE/ | ADD | 414,888 | 708,647 | +70.8% | $22.5M | 2026-Q1 |
| Connor, Clark & Lunn Investment Management Ltd. | ADD | 118,205 | 184,104 | +55.7% | $5.8M | 2026-Q1 |
| PANAGORA ASSET MANAGEMENT INC | DOUBLED | 21,856 | 142,327 | +551.2% | $4.5M | 2026-Q1 |
| Universal- Beteiligungs- und Servicegesellschaft mbH | DOUBLED | 32,263 | 70,053 | +117.1% | $2.2M | 2026-Q1 |
| FIRST TRUST ADVISORS LP | ADD | 38,313 | 68,470 | +78.7% | $2.2M | 2026-Q1 |
| Rafferty Asset Management, LLC | TRIM | 114,230 | 65,050 | -43.1% | $2.1M | 2026-Q1 |
| ENVESTNET ASSET MANAGEMENT INC | TRIM | 49,076 | 33,053 | -32.6% | $1.0M | 2026-Q1 |
| Marex Group plc | ADD | 8,200 | 12,000 | +46.3% | $380.6K | 2026-Q1 |
| Rockefeller Capital Management L.P. | DOUBLED | 230 | 1,151 | +400.4% | $36.5K | 2026-Q1 |
| CWM, LLC | ADD | 386 | 544 | +40.9% | $17.3K | 2026-Q1 |
| HRT FINANCIAL LP | TRIM | 77,640 | 46,745 | -39.8% | $1.5K | 2026-Q1 |
| Polar Capital Holdings Plc | EXIT | 1,008,163 | 0 | -100.0% | $0.00 | 2026-Q1 |
| WELLINGTON MANAGEMENT GROUP LLP | ADD | 5,800,003 | 8,079,608 | +39.3% | $219.4M | 2025-Q4 |
| Point72 Asset Management, L.P. | TRIM | 3,893,942 | 1,758,357 | -54.8% | $47.8M | 2025-Q4 |
| DIMENSIONAL FUND ADVISORS LP | DOUBLED | 257,083 | 651,716 | +153.5% | $17.7M | 2025-Q4 |
| Woodline Partners LP | DOUBLED | 199,291 | 500,127 | +151.0% | $13.6M | 2025-Q4 |
| D. E. Shaw & Co., Inc. | TRIM | 257,332 | 136,324 | -47.0% | $3.7M | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | ADD | 73,401 | 132,533 | +80.6% | $3.6M | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 194,588 | 118,488 | -39.1% | $3.2M | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 67,756 | 91,599 | +35.2% | $2.5M | 2025-Q4 |
| TD ASSET MANAGEMENT INC | TRIM | 92,450 | 66,570 | -28.0% | $1.8M | 2025-Q4 |
| ALPS ADVISORS INC | ADD | 31,916 | 54,559 | +70.9% | $1.5M | 2025-Q4 |
| Universal- Beteiligungs- und Servicegesellschaft mbH | ADD | 19,297 | 32,263 | +67.2% | $876.3K | 2025-Q4 |
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
6 SEC filing reports analyzed. Sentiment: 1 bullish, 1 bearish, 2 mixed, 2 neutral. Avg impact: 5.7/10.
BEARISH
PRESS-RELEASE
6/10
Celldex reported Q1 2026 EPS of -$1.18, missing consensus of -$1.07 by 10.8%. The press release focu
Jun 14, 2026
NEUTRAL
INST-CLUSTER
4/10
A mixed institutional cluster in CLDX for Q3 2025 shows two mega-passive buyers (Wells Fargo, Invesc
Jun 11, 2026
MIXED
8-K
6/10
Celldex reported Q1 2026 results with a net loss of $78.7M (-$1.18/share), wider than the $53.8M los
May 7, 2026
MIXED
PRESS-RELEASE
6/10
Celldex reported Q1 2026 EPS of -$1.18 (miss vs -$1.13 consensus) and revenue of $15K (miss vs $861K
May 7, 2026
NEUTRAL
424B5
5/10
Celldex Therapeutics is conducting a follow-on public offering of common stock to raise capital. The
Apr 1, 2026
BULLISH
INST-CLUSTER
7/10
Three major passive institutional investors — Morgan Stanley, Wells Fargo, and UBS — significantly i
Feb 28, 2026
BULLISH
7/10
Celldex presented positive Phase 1 data for CDX-622, a bispecific antibody targeting SCF and TSLP, a
Jun 14, 2026
NEUTRAL
4/10
Celldex announced three presentations at EAACI 2026: two flash talks on barzolvolimab's clinical pro
Jun 10, 2026
NEUTRAL
5/10
Celldex Therapeutics closed an underwritten public offering of 11.9 million shares at $29.00 per sha
Apr 6, 2026
NEUTRAL
5/10
Celldex Therapeutics priced a public offering of 10,345,000 shares at $29.00 per share, raising appr
Apr 2, 2026
NEUTRAL
4/10
Celldex Therapeutics announced a public offering of its common stock, with underwriters granted a 30
Apr 1, 2026
BULLISH
8/10
Celldex Therapeutics presented positive Phase 2 data for barzolvolimab in chronic spontaneous urtica
Mar 27, 2026
BULLISH
8/10
Celldex Therapeutics presented positive Phase 2 open-label extension data for barzolvolimab in ColdU
Mar 1, 2026
Current analyst consensus: Strong Buy (91% buy). Based on 22 analysts: 7 strong buy, 13 buy, 2 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$57.53 mean target
+84.0% upside
Strong Buy (1.25)
$38.00 Low
$90.00 High
| Metric | Value |
|---|---|
| Current Price | $31.27 |
| Target Low | $38.00 |
| Target Mean | $57.53 |
| Target Median | $54.00 |
| Target High | $90.00 |
| # Analysts | 15 |
| Recommendation | Strong Buy (1.25) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-1.07 | $-1.16 | $-0.92 | -25.3% | -0.3% | 4↑ 0↓ | $0.0B | 17.7% | 10 |
| Next Q 2026-09-30 |
$-1.08 | $-1.20 | $-0.94 | -7.0% | -0.1% | 4↑ 1↓ | $0.0B | 0.0% | 10 |
| Current FY 2026-12-31 |
$-4.39 | $-4.57 | $-4.03 | -12.6% | -0.1% | 6↑ 0↓ | $0.0B | 70.5% | 10 |
| Next FY 2027-12-31 |
$-4.50 | $-5.46 | $-3.78 | -2.4% | +1.1% | 6↑ 1↓ | $0.0B | 354.0% | 10 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-1.065 | |
| 7d ago | $-1.061 | -0.004 |
| 30d ago | $-1.061 | -0.004 |
| 60d ago | $-1.198 | +0.133 |
| 90d ago | $-1.215 | +0.150 |
5 analyst firms have rated this stock: 1 upgrades, 0 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Jun 10, 2026 | UBS | MAINTAIN | Buy | Buy |
| May 13, 2026 | Wells Fargo | MAINTAIN | Overweight | Overweight |
| May 8, 2026 | Barclays | MAINTAIN | Overweight | Overweight |
| Apr 20, 2026 | Barclays | UPGRADE | Underweight | Overweight |
| Mar 2, 2026 | Goldman Sachs | MAINTAIN | Neutral | Neutral |
| Feb 26, 2026 | Stifel | REITERATE | Buy | Buy |
| Dec 17, 2025 | Barclays | MAINTAIN | Underweight | Underweight |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 7 | 13 | 2 | 0 | 0 | 91% | |
| May 1, 2026 | 7 | 13 | 2 | 0 | 0 | 91% | |
| Apr 1, 2026 | 7 | 12 | 2 | 1 | 0 | 86% | |
| Mar 1, 2026 | 6 | 12 | 3 | 1 | 0 | 82% | |
| Feb 1, 2026 | 6 | 12 | 3 | 1 | 0 | 82% | |
| Jan 1, 2026 | 6 | 12 | 3 | 1 | 0 | 82% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
60°
Warm
Bearish
Neutral
Bullish
1 mentions
1 bullish
0 bearish
1 time period
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| Apr 20, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
Recent Reddit Threads
Jun 14, 2026
earnings
Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at the European Academy of Allergy and Clinical Immunology Annual Meeting
<p align="left">HAMPTON, N.J., June 14, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today the presentation of <a href="https://www.glob
Jun 14, 2026
fda
Celldex Presents Positive First-in-Human Results from Phase 1 Study of Novel Bispecific CDX-622 at the European Academy of Allergy and Clinical Immunology Annual Meeting
<p>HAMPTON, N.J., June 14, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) today presented <a href="https://www.globenewswire.com/Tracker?data=3MMT63
Jun 10, 2026
fda
Celldex Announces Multiple Upcoming Presentations from Leading Mast Cell Targeting Pipeline at the Upcoming 2026 European Academy of Allergy and Clinical Immunology Annual Congress
<p align="center">-- Flash talks on barzolvolimab clinical program in CSU and Cold Urticaria --<br>-- Late-breaking poster presentation on CDX-622 --<
Jun 1, 2026
Clinical Trial
A Study of CDX-0159 in Patients With Eosinophilic Esophagitis
Phase Phase 2 — COMPLETED
May 7, 2026
earnings
Celldex Reports First Quarter Financial Results and Provides Corporate Update
<p>HAMPTON, N.J., May 07, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) today reported financial results for the first quarter ended March 31, 2026
Apr 30, 2026
earnings_calendar
CLDX Q1 2026 Earnings Scheduled — 2026-04-30
Apr 29, 2026
Clinical Trial
FLT3 Ligand Immunotherapy and Stereotactic Radiotherapy for Advanced Non-small Cell Lung Cancer
Phase Phase 2 — COMPLETED
Apr 13, 2026
other
Celldex to Present at Upcoming Investor Conference
<p align="justify">HAMPTON, N.J., April 13, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today that management will participate in a fir
Apr 6, 2026
activist
Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
<p>HAMPTON, N.J., April 06, 2026 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX) today announced the clos
Apr 2, 2026
offering
Celldex Announces Pricing of $300 Million Public Offering of Common Stock
<p align="justify">HAMPTON, N.J., April 01, 2026 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX) today an
Apr 2, 2026
Clinical Trial
A Study of Barzolvolimab in Patients With Prurigo Nodularis
Phase Phase 2 — ACTIVE_NOT_RECRUITING
Apr 2, 2026
clinical_trial_readout
T-60d Trial Readout: barzolvolimab (Phase 2)
Trial: A Study of Barzolvolimab in Patients With Prurigo Nodularis
Sponsor: Celldex Therapeutics
Phase: Phase 2 | Status: ACTIVE_NOT_RECRUITING
Condit
Apr 1, 2026
offering
Celldex Announces Proposed Public Offering of Common Stock
<p align="justify">HAMPTON, N.J., April 01, 2026 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX) today an
Apr 1, 2026
clinical_trial_readout
T-90d Trial Readout: barzolvolimab (Phase 2)
Trial: A Study of Barzolvolimab in Patients With Prurigo Nodularis
Sponsor: Celldex Therapeutics
Phase: Phase 2 | Status: ACTIVE_NOT_RECRUITING
Condit
Mar 30, 2026
clinical_trial_readout
T-90d Trial Readout: barzolvolimab (Phase 2)
Trial: A Study of Barzolvolimab in Patients With Prurigo Nodularis
Sponsor: Celldex Therapeutics
Phase: Phase 2 | Status: ACTIVE_NOT_RECRUITING
Condit
Mar 30, 2026
clinical_trial_readout
T-90d Trial Readout: barzolvolimab (Phase 2)
Trial: A Study of Barzolvolimab in Patients With Prurigo Nodularis
Sponsor: Celldex Therapeutics
Phase: Phase 2 | Status: ACTIVE_NOT_RECRUITING
Condit
Mar 27, 2026
fda
Celldex Presents Positive Data from Phase 2 Chronic Spontaneous Urticaria and Phase 2 Cold Urticaria and Symptomatic Dermographism Studies Demonstrating Rapid, Profound and Durable Improvements in Patient Quality of Life at AAD 2026
<p><em>- Improvements seen across all six DLQI Domains indicating broad, beneficial impact on quality of life -</em><br><em>- Data further d</em><em>e
Mar 23, 2026
short_volume
Short Volume: CLDX — 57.3% short (0.4M / 0.7M)
Short: 406,075 | Exempt: 0 | TRF Vol: 708,936 | Short Ratio: 57.3% | Off-exchange volume (dark pool + OTC)